View:
United States securities and exchange commission logo
December 3, 2020
Andrew McDonald
Chief Executive Officer
LifeSci Acquisition Corp.
250 W. 55th St., #3401
New York, NY 10019
Re: LifeSci Acquisition
Corp.
Revised Preliminary
Proxy Statement on Schedule 14A
Filed November 27,
2020
File No. 001-39244
Dear Mr. McDonald:
We have reviewed your filing and have the following comment. If
you do not believe
our comment applies to your facts and circumstances, please tell us why
in your response. After
reviewing your response, we may have additional comments.
Revised Preliminary Proxy Statement on Schedule 14A filed November 27,
2020
Q: Do any of LSAC s directors or officers have interests that may
conflict with my interests with
respect to the Business Combination?, page 9
1. With reference to prior
comment 2, we note your disclosures on page 92 indicating that
Chardan served as
financial advisor to LSAC during the merger negotiations. Please
revise to explain what,
if any, compensation was or is payable to Chardan for rendering
these or other
services.
We remind you that the company and its management are
responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
action by the staff. Please contact Abby Adams at (202) 551-6902 or Joe
McCann at (202) 551-
6262 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Giovanni Caruso